Pfizer completes acquisition of InnoPharma

The company believes that the acquisition will help them build a strong sterile injectables pipeline in the oncology and central nervous disorders areas

id-10064000

The company has received regulatory approval from all government authorities for the acquisition

Pfizer has announced that it has completed the acquisition of the pharmaceutical development company, InnoPharma. The company has received regulatory approval from all US government authorities required by the agreement and other closing conditions.

"We believe this acquisition will help Pfizer build a strong sterile injectables pipeline in areas such as oncology and central nervous disorders. Sterile injectables is one of the several areas of potential growth. This acquisition reflects our continued view that attractive growth opportunities, both external and organic, exist for the business," said Mr John Young, group president, Pfizer Global Established Pharma (GEP).

 

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email

X